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1. Introduction 
Most of the studies that focus on the 
Alzheimer’s disease (AD) prediction forecast 
a dementia label: cognitively normal, mild 
cognitive impairments or AD. However, 
these labels cannot always be compared 
across cohorts, they are not perfectly 
accurate and they describe the disease 
thanks to a limited number of stages (only 3) 
contrary to what is, in practice, a continuous 
progression. For these reasons, we predict 
the Mini-Mental State Examination (MMSE), 
a cognitive test whose scale presents 30 
discrete values. Predicting this measure, 
assessed in multiple AD-related cohorts, 
allows better staging of the disease 
progression at the individual level, in 
particular in the ADNI, AIBL and 
PharmaCOG cohorts.  
 
2. Methods  
2.1 Model calibration 
The Bayesian mixed-effects model 
introduced in [1] allows to estimate the 
average temporal progression of biomarkers 
out of individual longitudinal data, i.e. 
repeated measurements over time. This 
group-average scenario is calibrated on the 
ADAS, MMSE, MOCA, RAVLT, Boston 
Naming Test, CDR-SoB, Geriatric 
Depression Score, Category Fluency 
(Animals) assessments of the ADNI 
database, letting aside the stable cognitively 
normal (CN) subjects. Selected individuals 
are thus CN converters, mild cognitive 
impaired (MCI) subjects with stable 
diagnosis, MCI converting to AD and stable 
AD. The group-average scenario describes 
the continuous conversion of each biomarker 
from a normal to an abnormal state in the 
form of a logistic curve, reconstructed from 
individual measurements with potentially 
missing values [2]. In a cross-validation 
setting (10 splits of 70/30% between train 
and test), it is possible to hide future values 
of test patients to forecast them (1.5, 3.0, 4.5 
and 6.0 years after the last seen visit). The 
prediction is compared to the real value that 
has been hidden during the personalization 
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Figure 1: MMSE forecast absolute errors (AE) with respect to time to prediction (years after the last 
known visit). Boxplots whiskers correspond to the 5th and 95th percentile. Outliers have been removed 
for the sake of clarity. The (# number) indicates the number of predictions at each temporal horizon. 
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2.2 Model comparisons 
Our forecast errors are compared to those 
obtained with (i) constant predictions, i.e. no 
change in MMSE score, (ii) individual linear 
regressions of patients’ past scores with 
respect to their past ages, and (iii) individual 
logit regressions. Besides, they are 
compared to the best achievable forecast 
which is the noise in the data. It has been 
measured in [3] – thanks to test-retests 
assessments including inter and intra-rater 
variability – leading to a standard deviation of 
2.8 out of 30. 
 
2.3 Cohort replications 
Although the previous group-average 
scenario of biomarkers progression has 
been calibrated on 8 cognitive tests, it is 
possible to personalize it to patients that only 
present a subset of these assessments. 
Thanks to this, we personalized the model to 
patients from the AIBL and PharmaCOG 
cohorts so to forecast their MMSE scores. 
Due to cohorts variability (especially the 
number of follow-up visits available / the time 
patients were followed), we evaluate 







(a) MMSE prediction errors on the AIBL cohort 1.5, 









(b) MMSE prediction errors on the PharmaCOG 
cohort 1.5, 2.0 and 2.5 years ahead. 
 
3. Results and discussion 
Figure 1 shows our forecasts on the ADNI 
cohort. While the linear and logit regressions 
present poor predictive power, the constant 
prediction, even if trivial, is somehow 
accurate (especially at short temporal 
horizons) due to the fact that the disease 
settles over long periods of time. 
Nevertheless, at any time horizon, our 
method predicts MMSE scores as well as or 
better than any of these techniques, and 
often with a lower dispersion. Besides, for 
some conditions, distributions of absolute 
errors compare with the intrinsic level of 
noise in the data. This comparison stresses 
the fact that short-term forecasts are 
worthless as the constant prediction already 
achieves noise level prediction. Furthermore, 
our model does not overfit and correctly 
estimates the long-term progression of the 
biomarkers as its personalization to patients 
of the AIBL and PharmaCOG cohorts shows 
prediction of the noise level or below 
constant prediction, outperforming the linear 
and logit regressions [Figure 2]. 
4. Conclusions 
The constant prediction outperforms 
standard regression techniques and is of 
noise level for small temporal horizons (up to 
2 or 3 years). Such comparison should 
always be undertaken in a forecasting 
context to evaluate a minimal temporal 
horizon for worthy predictions.  
Additionally, our model has proven to 
accurately estimate the average scenario of 
biomarkers progression. The latter, once 
personalized to individual data, enables to 
accurately forecast the MMSE for a wide 
range of times to prediction, even for patients 
from unseen cohorts (potentially having 
fewer cognitive assessments). This paves 
the way to accurate and robust prediction in 
real-life applications.  
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Figure 2: Replication of the MMSE forecasts on 
patients from AIBL and PharmaCOG cohorts – the 
model having been fitted on ADNI subjects only. 
